

COVAX

CEPI



unicef



COVAX Allocation Round 15

Vaccine Allocation Decision Proposal

April 11, 2022

Table of Contents

Round 15 Background

- ☐ Introduction
- ☐ Round Participant Scope and Overview
- ☐ Round Demand Overview
- ☐ Round Supply Overview
- ☐ Humanitarian Buffer
- ☐ Overview of Methodology

Round Proposal

- ☐ Round Outcome - Allocations
- ☐ Descriptive Statistics Summary
- ☐ Overview Graphs

Annexes

- ☐ COVAX Allocation Phase 2
- ☐ Policy Updates
- ☐ Additional Allocations

Introduction

Context for COVAX Allocation Round 15

- COVAX Allocation Round 15 (R15) is the first allocation round of Phase 2 and allocates available vaccine supply to participants for a six-month period, namely from April to September 2022 (inclusive).
- As per COVAX Phase 2 principles and objectives, R15 focuses on meeting the demand expressed by AMC (Advance Market Commitment) participants in line with their national targets.
- Similarly to Round 14, and as per Phase 2 principles, APA (Advance Purchase Agreement) doses and donated doses are allocated together in R15.

Nb of eligible participants (AMC)	R15 Total Demand (estimate)
91 ¹	176,978,429

- COVAX had sufficient supply to meet the demand in this Round and expects this situation to continue in subsequent rounds. However, it is important to note that demand is not expected to remain static: as the pandemic, public health recommendations and national contexts continue to evolve, countries' strategies and needs will continue to be dynamic. COVAX will work with countries to regularly update, refine and increase demand estimates where possible. Further requests will be fulfilled through subsequent allocations.
- Information on previous COVAX allocation rounds are available on the WHO website ([web link](#)).

1. Number of countries is AMC 92 excluding India, whose doses are allocated in a separate process – see slide 4.

Round 15 Demand (estimate) and participants receiving allocations

Participant Scope

COVAX Facility Participants

- Only AMC participants are allocated doses under Phase 2. Self-Financing Participants (SFPs) are managed through a separate process.
- There are 92 Advance Market Commitment (AMC) Participants. India's allocations are now managed through a different process; therefore, the Facility considers 91 AMC participants for the purpose of allocations.

Round Participants

- Participants' demand was gathered through the COVAX demand planning workstream, which actively engaged with participants on their need for this supply period. This includes monthly demand, by product, based on participants' national targets.
- The demand data were frozen on 15th March at 6.00pm CET.

Of the 91 AMC participants:

3 participants are not included in R15 since they have opted out of COVAX or have no vaccination programs currently in place.

88 participants were included in R15, of which 61 received an allocation:

- 53 expressed their needs through the COVAX demand planning process
- For 8 participants, demand was extrapolated based on estimated needs, allocated product being determined based on historical preferences the countries had expressed

27 participants did not receive an allocation under R15:

- 15 who did not express demand for more doses at this time had received offers of long-term Pfizer supply (i.e. the 'baseload') in January
- 12 expressed a 0-dose COVAX demand for the allocation period of this round.

- **Product preference** was based on demand plans submitted by participants. In case of shortage of products, and in the absence of alternatives in the demand plan, the Facility based the allocation on preference information from the COVAX Collaboration Platform (deadline for changes was 2 March) and confirmed with products accepted in the past.


- **No coverage caps were applied in Round 15**

Round 15 Demand (est.) Overview

Overview of Total demand for R15

Total participant demand (doses) for products expressed in R15 (for Q2 and Q3 2022) including extrapolated¹ demand: **177.0M**

Product	Initial ² demand (M)	Effective ² demand (M)
Janssen – Ad26.COV 2-S	56.2	73.6
AstraZeneca – Vaxzevria	45.8	16.1
Moderna – mRNA-1273	28.7	30.9
Pfizer BioNTech - Comirnaty	27.1	42.1
Sinovac	8.4	8.4
SII - COVISHIELD	5.4	0.4
Sinopharm	3.2	3.2
SII - Covovax	2.3	2.3
Total	177.0	177.0




Number is millions of doses rounded up

1. Demand was extrapolated for eight participants, estimated as 1% of their population per month

2. Because several countries opted out of AZ and Covishield after the demand planning exercise was completed, the respective initial demand was replaced with J&J, Moderna and Pfizer doses

Round 15 Final Demand (est.)

- The extrapolated demand for the 8 participants that did not submit a forecast amounts to **11.3M doses**
- **An additional 15%** is added to the total demand submitted, as an additional offer to participants in order to meet additional potential needs (such as boosters, etc.). This additional 15% offer is based on two principles:
 - Product preference: additional doses allocated either to products the Participant has already expressed a demand for, or Participant's 1st preference product, and if those options were not possible, to their 2nd preference product (based on CCP data)
 - Participants received an offer for Covovax if the product was considered as a desirable or highly desirable product
- The additional 15% offer is applied to all products except Pfizer, considering the specific characteristics of the separate Pfizer baseload allocation process.
- **Total demand considered for Round 15 amounts to 199.5M doses**



Round 15 Supply Overview

Round Supply - Overview

COVAX Allocation Round 15

- Supply from donations and APA were pooled in accordance with Phase 2 principles. 7 products are available for R15, resulting in a total supply exceeding demand.
- In principle, doses of shelf life >16 weeks at the time of the offer letter are allocated through the process, while doses of shorter shelf life are handled in a separate process. Exceptionally for R15, and due to the need to match supply to demand AZ, doses of shorter shelf life (expiring in June) were allocated. Such AZ doses were allocated for a shipment in April.

Supply Source	Products
Round 15 APA Doses	SII-COVISHIELD
	SII - Covovax
	Janssen – Ad26.COV 2-S
	Moderna – mRNA-1273
	Sinopharm
Round 15 Donations	AstraZeneca – Vaxzevria
	Janssen – Ad26.COV 2-S (JnJ)
	Moderna – mRNA-1273
	Pfizer BioNTech – Comirnaty ³

Product Name	Minimum Shipment Size (doses)
AstraZeneca – Vaxzevria	1,400 or 1,920 ¹
SII-COVISHIELD	18,000
Moderna – mRNA-1273	1,200 or 10,080 ¹
Janssen – Ad26.COV 2-S	7,200 ²
SII - Covovax	12,000
Pfizer BioNTech - Comirnaty	1,170
Sinopharm	3,600

1. Depending on population size and operational and logistical requirements.

2. The manufacturer updated the minimum shipment size for Janssen – Ad26.COV 2-S . Shipment size is no longer linked to recipient country total population.

3. ~430M of this supply are considered 'facilitated doses' , part a US dose donation and in part a procurement facilitated by the government of the United States of America.

Round 15 Supply Overview

Round Supply Considerations

- In alignment with Phase 2 principles, the COVAX Facility has included confirmed donations with APA doses for R15 allocation. Round 15 considered for allocation offered doses from 23 donating countries. Donations and APA supply were matched with demand as per slide 12.

Overview of supply included in R15

Product	Total supply allocated ¹	R15 Allocation of Total Product Specific Supply
AstraZeneca – Vaxzevria	11,110,800	All supply used
SII-COVISHIELD	1,782,200	Partially used
Covovax	13,632,000	Partially used
Janssen – Ad26.COV 2-S	92,232,200	Partially used
Moderna – mRNA-1273	33,581,040	Partially used
Pfizer BioNTech - Comirnaty	46,431,450	Partially used
Sinopharm	2,296,800	All supply used
Sinovac	0	NA
Total	201,066,090	~1Bn

- Total doses allocated in R15 = 201,066,090**
 - 67.5% donations
 - 32.5% APA

The supply/demand data presented in this report was gathered 4 to 6 weeks ago and, as such, is a snapshot of the demand/supply landscape at that point in time:

- Supply is shifting by the potential to activate a phasing process and by the dynamics inherent to the dose-sharing process*
- Demand figures are preliminary and shifting as several factors can modify them in the visible future, including demand for boosters, uncertainty around new variants and an optimal schedule of 3-dose regimen, among others*
- The supply-demand balance is moving on a real-time basis and figures will be updated on a regular cadence. Significant mitigation actions that have dramatically reduced this difference have been pursued*

Humanitarian Buffer

Proposed Allocation to the Humanitarian Buffer (HB)

Product Name	Total Supply (doses)
-	-

Background to Proposed Allocation to the Humanitarian Buffer

- In light of Phase 2 and the intent to meet real-time demand, COVAX has revisited the approach for allocating doses to the Humanitarian Buffer.
- Starting with R15, COVAX will rely on rolling allocations to the HB and allocate doses for all confirmed demand (approved applications) made to the humanitarian buffer up to the total of 5% of all allocated AMC doses. The demand will be assessed monthly, to coincide with each allocation round, and supply will be allocated based on that information.
- Given the HB demand from prior rounds has been met, and there are currently no applications under review, there is no further allocation to the HB under R15.
- There is a virtual accounting of the 5% doses that will remain available for future allocations.

Round 15 Overview of methodology

Allocation Methodology for R15

- Based on Phase 2 allocation principles and objectives, R15 aims to allocate doses according to participants' product requests and, if this is not possible, to meet their second preferred products **giving priority to lower coverage countries**.
- The **main steps of the algorithm** are described below:
 1. Countries are ranked by coverage in ascending order
 2. The allocation of the first month's supply (in this case April) takes place respecting the above order:
 - i. The requested products are the first to be allocated up to participant demand, provided there is sufficient supply
 - ii. If supply is not sufficient to meet the products requested, the algorithm resorts to the participant's demand plan in order to identify substitute products to meet the demand. In the absence of this information, product preferences are extracted from the COVAX Collaboration Platform (CCP) and the participant's demand is met with "highly desirable" or "desirable" products.
 3. Step 2 is repeated for each month through and including September 2022
 4. An additional 15% supply is allocated to countries by repeating Steps 2 and 3 above:
 - i. The 15% is offered as a percentage of each of the products that the participant has requested
 - ii. If a participant has expressed a preference for Covovax (either through the demand plan template or the CCP), the entire 15% of additional supply is made up of Covovax.
 - iii. The rationale behind offering this additional supply is to allow Participants to meet dynamic needs, such as boosters, etc., while respecting Participants' preferences. The 15% figure is chosen based on participants' feedback during bilateral discussions with country-facing staff.

Round 15 Outcome

Round 15 Outcome

Key Figures for COVAX Allocation Round 15



Demand and product preference information

- **100% of the participants have received the number of doses they requested.**
- Out of the **177M** doses requested by participants, approximately **128M** doses (**72%**) were allocated with the requested product. The above percentage includes three countries that opted out of specific products in a very late stage of the allocation process and were allocated a substitute product instead. (By excluding those countries from the calculation, the percentage increases to **82%**; **105 of 127M** doses were allocated with the requested product.)
- For the remaining **49M** doses requested by participants, the specific products were allocated using the information available in the participants demand plans. If the latter was not available, the information in the COVAX Collaboration Platform (CCP) was used in its place (products characterized as “highly desirable” or “desirable”)
- An additional **22.5M** (15%) doses were offered to all participants with stated demand for any product except Pfizer (see slide 12) to meet additional needs (boosters, additional demand from improved delivery support, etc)



Total doses allocated

- **Total doses allocated in R15 = 201,066,090**
 - 67.5% donations
 - 32.5% APA

Allocation snapshot

Product	Total allocated ¹
AstraZeneca – Vaxzevria	11,110,800
SII-COVISHIELD	1,782,200
Covovax	13,632,000
Janssen – Ad26.COV 2-S	92,232,200
Moderna – mRNA-1273	33,581,040
Pfizer BioNTech - Comirnaty	46,431,450
Sinopharm	2,296,800
Sinovac	0
Total	201,066,090

1. Rounded up figures due to batch sizes.

Round 15 Allocation Outcome (1 of 4)

Participant Name (in alphabetical order)	WHO Region	AstraZeneca - Vaxzevria	SII- COVISHIELD	SII- COVOVAX	Janssen- Ad26.COV 2-S	Moderna- mRNA- 1273	Pfizer BioNTech - Comirnaty	Wuhan CNBG – Inactivated (Sin opharm)	Total R15 doses	Population Covered* (%)
Afghanistan	EMRO	0	0	0	7,084,800	0	0	0	7,084,800	24.8%
Algeria	EMRO	0	0	0	0	0	0	0	0	67.2%
Angola	AFRO	0	0	0	0	0	0	0	0	86.3%
Bangladesh	SEARO	0	0	0	0	0	27,252,810	0	27,252,810	152.9%
Benin	AFRO	0	0	0	1,468,800	40,320	0	0	1,509,120	47.1%
Bhutan	SEARO	0	36,000	0	0	679,200	0	0	715,200	154.9%
Bolivia	PAHO	0	0	0	3,520,800	0	0	0	3,520,800	131.9%
Burkina Faso	AFRO	0	0	0	2,692,800	0	0	0	2,692,800	41.2%
Cabo Verde	AFRO	0	0	0	0	0	0	0	0	113.5%
Cambodia	WPRO	0	0	0	0	0	2,000,700	0	2,000,700	131.9%
Cameroon	AFRO	0	0	0	0	0	0	0	0	25.0%
Central African Republic	AFRO	0	0	0	151,200	0	0	0	151,200	53.5%
Chad	AFRO	0	0	0	1,166,400	0	0	0	1,166,400	36.4%
Comoros	AFRO	0	0	0	0	0	0	0	0	88.2%
Congo	AFRO	0	0	0	0	0	0	0	0	84.3%
Côte d'Ivoire	AFRO	0	288,000	0	0	0	0	0	288,000	54.9%
Democratic Republic of the Congo	AFRO	0	0	0	4,060,800	1,732,320	0	0	5,793,120	26.5%
Djibouti	EMRO	0	0	0	64,800	0	0	0	64,800	68.7%
Dominica	PAHO	16,080	0	0	0	0	31,590	0	47,670	178.3%
Egypt	EMRO	0	0	0	0	3,535,200	3,074,760	0	6,609,960	105.9%
El Salvador	PAHO	0	0	0	0	403,200	0	0	403,200	111.6%

* «Population covered» is the fraction of the population with a hypothetical 2-dose coverage (all sources of supply considered) after Round 15 allocation and including the doses shipped in previous rounds.

Round 15 Allocation Outcome (2 of 4)

Participant Name	WHO Region	AstraZeneca - Vaxzevria	SII-COVISHIELD	SII-COVOVAX	Janssen-Ad26.COV 2-S	Moderna-mRNA-1273	Pfizer BioNTech - Comirnaty	Wuhan CNBG – Inactivated (Sinopharm)	Total R15 doses	Population Covered* (%)
Eswatini	AFRO	0	0	0	86,400	0	0	0	86,400	50.8%
Ethiopia	AFRO	0	0	0	8,316,000	0	0	0	8,316,000	48.9%
Fiji	WPRO	0	0	0	0	74,160	0	0	74,160	98.3%
Gambia	AFRO	0	0	0	172,800	12,000	0	0	184,800	39.1%
Ghana	AFRO	44,720	504,000	0	0	0	0	0	548,720	68.7%
Grenada	WPRO	0	0	0	0	0	0	0	0	81.4%
Guinea	AFRO	529,920	0	0	1,389,600	769,200	0	644,400	3,333,120	64.4%
Guinea-Bissau	AFRO	11,520	0	0	352,800	0	0	0	364,320	63.8%
Guyana	WPRO	7,680	0	0	64,800	0	0	0	72,480	80.0%
Haiti	WPRO	0	0	0	0	414,240	0	0	414,240	12.7%
Honduras	WPRO	0	0	0	0	0	0	0	0	85.8%
Indonesia	SEARO	0	0	2,256,000	0	15,009,840	0	0	17,265,840	93.9%
Kenya	AFRO	1,201,560	0	0	5,234,400	1,745,280	0	0	8,181,240	63.6%
Kiribati	WPRO	0	0	0	0	0	0	0	0	100.9%
Kosovo (in accordance with UN Security Council resolution 1244 (1999))	EURO	0	0	0	0	0	250,380	0	250,380	90.8%
Kyrgyzstan	EURO	0	0	0	0	81,600	0	0	81,600	43.7%
Lao People's Democratic Republic	WPRO	501,120	0	0	0	0	1,075,230	0	1,576,350	113.6%
Lesotho	AFRO	0	0	0	0	0	0	0	0	80.2%
Liberia	AFRO	0	0	0	302,400	0	0	0	302,400	51.8%
Madagascar	AFRO	390,760	0	0	1,648,800	0	0	0	2,039,560	37.3%
Malawi	AFRO	0	0	0	5,551,200	0	0	0	5,551,200	58.6%
Maldives	SEARO	0	0	0	0	0	0	0	0	138.2%

* «Population covered» is the fraction of the population with a hypothetical 2-dose coverage (all sources of supply considered) after Round 15 allocation and including the doses shipped in previous rounds.

Round 15 Allocation Outcome (3 of 4)

Participant Name	WHO Region	AstraZeneca - Vaxzevria	SII- COVISHIELD	SII- COVOVAX	Janssen- Ad26.COV 2-S	Moderna- mRNA-1273	Pfizer BioNTech - Comirnaty	Wuhan CNBG – Inactivated (Sinopharm)	Total R15 doses	Population Covered* (%)
Mali	AFRO	51,840	0	1,224,000	0	0	1,020,240	302,400	2,598,480	35.0%
Mauritania	AFRO	0	0	0	0	0	0	0	0	70.1%
Micronesia (Federated States of)	WPRO	0	0	0	0	0	0	0	0	57.3%
Mongolia	WPRO	0	0	0	0	0	0	0	0	100.2%
Morocco	EMRO	0	0	2,592,000	0	0	0	0	2,592,000	116.8%
Mozambique	AFRO	0	0	0	0	0	0	0	0	90.0%
Nepal	SEARO	0	0	0	13,802,400	5,760,000	3,004,560	0	22,566,960	142.7%
Nicaragua	PAHO	0	0	0	0	0	0	0	0	82.8%
Niger	AFRO	0	0	0	1,987,200	0	0	0	1,987,200	34.8%
Nigeria	AFRO	0	0	0	3,967,200	0	0	0	3,967,200	40.8%
West Gaza and Gaza	EMRO	0	0	0	0	0	294,840	0	294,840	99.3%
Pakistan	EMRO	0	0	4,164,000	0	0	0	1,054,800	5,218,800	57.8%
Papua New Guinea	WPRO	0	0	0	180,000	40,080	0	36,000	256,080	11.4%
Philippines	WPRO	0	0	0	0	0	0	0	0	119.6%
Republic of Moldova	EURO	0	0	0	36,000	255,840	0	0	291,840	50.1%
Rwanda	AFRO	0	0	0	0	0	0	0	0	93.8%
Saint Lucia	PAHO	0	0	0	0	9,600	0	0	9,600	77.3%
Saint Vincent and the Grenadines	PAHO	2,800	0	0	0	10,800	0	0	13,600	113.4%
Samoa	WPRO	0	0	0	0	0	0	0	0	109.2%
Sao Tome and Principe	AFRO	0	0	0	0	0	0	0	0	115.6%
Senegal	AFRO	0	0	0	691,200	0	0	0	691,200	52.4%

* «Population covered» is the fraction of the population with a hypothetical 2-dose coverage (all sources of supply considered) after Round 15 allocation and including the doses shipped in previous rounds.

Round 15 Allocation Outcome (4 of 4)


Participant Name	WHO Region	AstraZeneca - Vaxzevria	SII-COVISHIELD	SII-COVOVAX	Janssen- Ad26.COV 2-S	Moderna- mRNA- 1273	Pfizer BioNTech - Comirnaty	Wuhan CNBG – Inactivated (Sinopharm)	Total R15 doses	Population Covered* (%)
Sierra Leone	AFRO	300,880	0	0	741,600	0	0	0	1,042,480	51.9%
Solomon Islands	WPRO	0	0	0	0	0	42,120	0	42,120	50.3%
Somalia	EMRO	882,000	0	0	4,773,600	0	0	0	5,655,600	59.8%
South Sudan	AFRO	0	0	0	2,073,600	0	0	0	2,073,600	35.7%
Sri Lanka	SEARO	0	0	0	0	0	0	0	0	100.8%
Sudan	EMRO	2,085,120	0	0	1,468,800	0	0	0	3,553,920	45.4%
Syrian Arab Republic	EMRO	1,893,440	954,000	0	0	0	0	0	2,847,440	48.2%
Tajikistan	EURO	501,120	0	0	0	0	2,156,310	0	2,657,430	81.9%
Timor-Leste	WPRO	0	0	0	0	0	0	0	0	62.6%
Togo	AFRO	0	0	0	0	0	0	0	0	57.1%
Tonga	WPRO	0	0	0	0	0	7,020	0	7,020	78.8%
Tunisia	EMRO	0	0	0	0	0	0	0	0	97.0%
Tuvalu	WPRO	10,480	0	0	0	0	0	0	10,480	176.0%
Uganda	AFRO	0	0	0	0	2,867,760	5,859,360	0	8,727,120	84.6%
Ukraine	EURO	0	0	0	7,444,800	0	0	0	7,444,800	102.6%
United Republic of Tanzania	AFRO	0	0	0	4,600,800	0	0	0	4,600,800	28.6%
Uzbekistan	EURO	0	0	2,604,000	0	0	0	0	2,604,000	106.1%
Vanuatu	WPRO	0	0	0	0	140,400	0	0	140,400	74.6%
Viet Nam	WPRO	0	0	0	0	0	0	0	0	138.7%
Yemen	EMRO	202,560	0	0	0	0	361,530	0	564,090	4.8%
Zambia	AFRO	1,440,400	0	0	7,135,200	0	0	259,200	8,834,800	68.2%
Zimbabwe	AFRO	0	0	0	0	0	0	0	0	72.0%

* «Population covered» is the fraction of the population with a hypothetical 2-dose coverage (all sources of supply considered) after Round 15 allocation and including the doses shipped in previous rounds.

COVAX has allocated more than 2 billion doses and shipped 1.4 billion doses to 144 Participants to date in 15 allocation rounds

As of 28th March 2022

Doses allocated to date by COVAX¹ (excl. cost sharing), Millions



2 Billion doses allocated

1.4 Billion doses shipped

15 Allocation rounds

144 Participants received shipments¹

1. Out of 153 Participants, excluding Team Europe, 61 of which received allocations

Supply coverage overview from all sources incl. Round 15 allocation – AMC 91


MARCH 15TH COVAX DATA / MARCH 2ND GMA DATA / MARCH 2ND STOCK DATA

■ Two-doses vaccinated equivalent¹, in country stock² (2DE³), COVAX and cost-sharing doses allocated, not shipped (2DE), Non-COVAX doses⁴ (2DE)

■ Round 15 Allocation (2DE)

Projected supply available per participant, expressed as 2-dose population coverage, including: two-doses vaccinated equivalent, in country stock, doses allocated through COVAX (R1-15, donations, reallocations), cost-sharing, and other sources of supply projected by end of Q3 2022 (n=88⁵)

2-dose supply population coverage, % sorted descending



- Round 15 allocated doses to all Participants according to their demand without caps
- 201 million doses were allocated, of which:
 - 19% (37 million) of doses went to participants with supply below 40%
 - 48% (97 million) were allocated to participants with supply below 70%
- 670 million doses are needed for all countries to get to 70%
- 117 million doses are needed for all countries to get to 40%

1. Estimated by total doses administered divided by 2 (assumes 2-dose regimen) ; 2. Doses received including GMA, with a deduction of administered doses and a 10% wastage of total doses; 3. Two-doses equivalent; 4. Other sources of supply include bilateral deals, multilateral supply (including AVAT), donations, and domestic production until end of Q3 2022 (GMA data); a pro-rated proportion of Q1 non-COVAX supply is assumed to be already shipped and is excluded to avoid overlap with in-country stock data; 5 AMC 91 excluding countries not participating in COVAX: Eritrea, Burundi and Marshall Islands

Annexes

COVAX Allocation Phase 2

Context for COVAX Allocation Round 15

Context

The COVAX Allocation Mechanism was launched in 2020 with the first allocations in February 2021. Since then, 1.87 billion doses have been allocated through 14 different allocation rounds and donations, and 1.38Bn doses shipped by COVAX to 144 countries. (as of March 18th)

Overall global supply has considerably increased, allowing COVAX to shift to a new phase, driven by participants' needs.

Phase 2 of the COVAX Allocation Mechanism

- The Phase 2 of the allocation mechanism, starting with Round 15, aims to reflect the changing environment around COVAX, notably available supply and the pandemic with the following goals:
 - Support all countries' individual targets and ambitions to control the disease and “reopen society” in 2022
 - Contribute to the vaccination coverage goals countries set for themselves, in view of the WHO-UN 2022 Global Vaccine Strategy coverage targets and in consideration of supply beyond COVAX.
- The allocation mechanism has evolved to prioritize participants with lower coverage towards achieving self-defined targets, up to their demand, enhancing supply security, and providing greater predictability of supply.

COVAX Allocation Phase 2


Context for COVAX Allocation Round 15

Phase 2 principles:

- Move from a push, supply-driven approach to a pull, **demand/absorption capacity driven approach**
- Continue to enhance **equity** by accounting for all sources of supply and prioritizing participants with lower coverage towards achieving self-defined targets, up to their absorption limits

Phase 2 objectives:

- Enhance **supply security** (maintaining diversity in COVAX portfolio)
- Provide **greater predictability** to participants and enhance **clarity** and understanding of the allocation for participants
- Enhance **simplicity and flexibility** to adapt to uncertainty and changing circumstances and reduce transaction costs
- Guarantee **continuity of supply** and support **tailored portfolio approach** for all, to enhance program implementation in line with SAGE recommendations



COVAX Allocation Phase 2

Context for COVAX Allocation Round 15

How Phase 2 changes applied to R15

- **Allocation driven by participant demand:** countries submit demand based on their own targets and supply is allocated accordingly
- All demand from participants is met in terms of volumes and 82% of those doses were allocated according to the requested product.
- **All sources of supply** are accounted for to establish country population coverage (and ranking) and enhance equity
- **A total of 7 products are available** for R15, enhancing supply security and maintaining diversity in the COVAX portfolio
- **Long-term rolling allocations** and ranges to reflect dynamic changes on the demand and supply side: allocation of supply is for the 6-month period of **April through September 2022 inclusive**. Future rounds will provide the opportunity for participants to update their demand information on a monthly basis, including for boosters and other increases in demand.
- **Update of the algorithm and logic applied:** in view of the demand-driven context, the algorithmic logic has been updated to offer a more tailored portfolio solution to countries
- **Self-Financing Participants:** The scope of phase 2 allocation is focused only on donor-funded, facilitated, and donated doses for AMC participants. Cost-sharing, Self-Financing participants (SFPs) and ancillaries (syringes and diluents) are managed through a different process.

Governance

- In Phase 2, the governance of the Allocation Mechanism has evolved in light of the shift to a demand-driven process and a less supply-constrained environment, with the IAVG oversight focusing on strategic monitoring and guidance.
- Starting with R15, considering the achievement of demand-based allocation, the IAVG transitions from its prior role in Phase 1 as approval body overseeing supply-constrained allocations to concurrence expert panel for Phase 2 Rounds, providing strategic monitoring of COVAX allocations

Resources Overview of COVAX allocations to date: <https://www.who.int/groups/iavg>

Strategy to Achieve Global Covid-19 Vaccination by mid-2022: <https://cdn.who.int/media/docs/default-source/immunization/covid-19/strategy-to-achieve-global-covid-19-vaccination-by-mid-2022.pdf>

Policy updates

Context for COVAX Allocation Round 15

Updates and Considerations for Round 15 and beyond

No coverage cap applied

- In January 2022, SAGE updated its *Roadmap on prioritizing the use of Covid-19 vaccines*. In accordance with the updated recommendation, the COVAX Facility removed the coverage cap of '70% from all sources'. **Starting R15, all AMC participants can request doses to meet their individual coverage targets, including boosters for individuals above 12 years of age.**

COVAX policy on pediatric doses

- SAGE recommends that countries prioritise highest and high priority use groups for delivery of primary series and booster - such as older adults, health care workers, immunocompromised, adults with comorbidities, pregnant persons, teachers & essential workers, and disadvantaged sociodemographic populations – ahead of medium and lowest priority-use groups. COVAX support for pediatric vaccination – for children aged 5-11 years old – is currently under consideration for countries that have successfully reached highest and high priority use groups.

Janssen two-dose recommendation

- While the Janssen vaccine received EUL for a single dose, SAGE published an updated recommendation in December 2021 for a 2-dose regimen. To that end, COVAX has updated its position to recommend Participants follow a 2-dose schedule for J&J, with the second dose to be given 2-6 months after the first dose. All AMC participants that have received J&J doses in the past as part of a single-dose regimen are eligible to receive a second dose to complete the schedule. Participants will nonetheless have the option to follow 1-dose schedule for some or all of their populations based on their national strategies.

Additional Allocations 1/2

Following R14 and prior to R15, the following allocations were processed and registered through the allocation portal. Additional coverage reached through these allocations was considered for R15:

- **Dose Sharing Round 44:** Donations of AstraZeneca and Moderna doses with shelf life <12 weeks processed outside formal allocation rounds.
- **ADMIN Round 14:** allocation of Pfizer doses to participants who expressed additional needs in advance of R15

Name	Participant	Product	Doses	Rationale
<u>DS-44</u>	Bangladesh	AstraZeneca - Vaxzevria	100,800	Donations of shorter shelf-life doses processed outside allocation rounds
	Bangladesh	AstraZeneca - Vaxzevria	1,749,600	
	Fiji	Moderna - Spikevax	60,480	
	Kenya	Moderna - Spikevax	302,400	
	Mali	AstraZeneca - Vaxzevria	24,000	
	Mali	AstraZeneca - Vaxzevria	50,400	
	Mali	AstraZeneca - Vaxzevria	26,400	
	Syrian Arab Republic	AstraZeneca - Vaxzevria	43,200	

Additional Allocations 2/2

Name	Participant	Doses	Product	Rationale
<u>ADMIN-14</u>	Bhutan	90,090	Pfizer BioNTech - Comirnaty	Additional doses requested by participants
	Bolivia	3,659,760		
	Cambodia	5,515,380		
	Comoros	90,090		
	Honduras	500,760		
	Kiribati	53,820		
	Lesotho	200,070		
	Maldives	402,480		
	Mozambique	10,635,300		
	Samoa	155,610		
	Sao Tome and Principe	37,440		
	Solomon Islands	52,650		
	Tuvalu	11,700		
	Vietnam	4,500,990		

COVAX

CEPI



Thank you